Open an account

Fate Therapeutics

FATE · NASDAQ

$2.06+$0.20 (+10.75%)TodayMarket closed ·
Prev close $1.86

About FATE

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 161 full-time employees. The company went IPO on 2013-10-01. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.

Employees
161
Headquarters
San Diego, California
Listed
Oct 1, 2013
Sector
Health Care
Industry
Biotechnology
Website
fatetherapeutics.com

FATE key statistics

Market cap
246.83M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.37M
Volume
1.77M
Open price
$1.86
High today
$2.15
Low today
$1.84
52 Week high
$3.23
52 Week low
$0.95

Fate Therapeutics (FATE) at a glance

As of Oct 20, 2026, Fate Therapeutics (FATE) shares are priced at $2.06, giving the company a market cap of 246.83M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.84 and $2.15. The current price is 12.0% above the day's low and 4.0% below its high.

Volume so far is 1.77M shares, above the average of 1.37M shares a day.

Over the past year Fate Therapeutics has ranged from $0.95 to $3.23, and now sits 49% of the way up that range.

Fate Therapeutics met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported -$0.25 per share against an estimate of -$0.2732.

The average analyst price target is $5.57, 170.5% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 6 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 10 analystsAvg $5.57
Low
$2.22
Now
$2.06
High
$8.40

FATE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 9.1% on average.

  1. Q3 FY24: reported -$0.40 per share against an estimate of -$0.4409
  2. Q4 FY24: reported -$0.44 per share against an estimate of -$0.4411
  3. Q1 FY25: reported -$0.32 per share against an estimate of -$0.3907
  4. Q2 FY25: reported -$0.29 per share against an estimate of -$0.3493
  5. Q3 FY25: reported -$0.27 per share against an estimate of -$0.2969
  6. Q4 FY25: reported -$0.27 per share against an estimate of -$0.2751
  7. Q1 FY26: reported -$0.26 per share against an estimate of -$0.2856
  8. Q2 FY26: reported -$0.25 per share against an estimate of -$0.2732

FATE news

  • Press releasePRNewswire

    A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

  • Press releaseGlobe Newswire

    After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

  • Press releaseGlobe Newswire

    Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

  • Press releasePRNewswire

    The $13 Million Company Teaching the Immune System to Hunt Cancer

  • Press releasePRNewswire

    Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

  • Press releasePRNewswire

    Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

  • Press releasePRNewswire

    Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

  • 10 Health Care Stocks Whale Activity In Today's Session

Similar companies

Companies in the same industry as Fate Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.